CoChat

Tenascin C in metastasis: A view from the invasive front

Open access
Lowy, Camille M, Oskarsson, Thordur · 2015 · Cell Adhesion & Migration

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

Abstract

The extracellular matrix protein tenascin C (TNC) is a large glycoprotein expressed in connective tissues and stem cell niches. TNC over-expression is repeatedly observed in cancer, often at the invasive tumor front, and is associated with poor clinical outcome in several malignancies. The link between TNC expression and poor survival in cancer patients suggests a role for TNC in metastatic progression, which is responsible for the majority of cancer related deaths. Indeed, functional studies using mouse models are revealing new roles of TNC in cancer progression and underscore its important contribution to the development of metastasis. TNC has a pleiotropic role in advancing metastasis by promoting migratory and invasive cell behavior, angiogenesis and cancer cell viability under stress. TNC is an essential component of the metastatic niche and modulates stem cell signaling within the niche. This may be crucial for the fitness of disseminated cancer cells confronted with a foreign environment in secondary organs, that can exert a strong selective pressure on invading cells. TNC is a compelling example of how an extracellular matrix protein can provide a molecular context that is imperative to cancer cell fitness in metastasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19336918.2015.1008331

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. TNC structure and cancer associated domains. TNC is a multifunctional glycoprotein composed of several distinct domains. (A) Domain structure of full length human TNC protein (based on ref. 11). At the N-terminus, the assembly domain (AD) mediates the oligomerization of the protein where 2 trimers form a hexameric structure. Between the EGF-like repeats and the carboxy terminal fibrinogen globe (FG) are Fibronectin type III repeats (FNIII). In human TNC, 9 of the total 17 FNIII repeats are alternatively spliced providing the possibility of multiple different TNC isoforms. (B) Several alternatively spliced FNIII repeats have been identified in cancer. FNIII domains A1 and C are expressed in lung cancer and A1 domain in renal cell carcinoma.39,40,52 Colorectal carcinoma (CRC) expresses domains A1, A2 and A4 which are specifically enriched in CRC when compared to total TNC expression.51 Head and neck cancer exhibits A1 and AD2 domains while melanoma expresses A1 and AD1.53–56 In urothelial carcinoma, domains A1, B, C and D are present and associate with invasive cancer.57,58 FNIII domain B is expressed in ovarian cancer and is enriched compared to the short TNC isoform (lacking all alternatively spliced FNIII domains).59 Breast cancer expresses B and D domains that are associated with invasive behavior and the AD1 domain.55,60 It is important to note that these lists are not exhaustive and only include the domains that have been positively linked to a particular cancer. Information of complete isoforms is generally lacking. However, while the knowledge of different TNC isoforms expressed in cancer is still rudimentary and incomplete, the appearance of different domains in cancers may indicate a requirement for distinct aspects of TNC functions.
Figure 1. TNC structure and cancer associated domains. TNC is a multifunctional glycoprotein composed of several distinct domains. (A) Domain structure of full length human TNC protein (based on ref. 11). At the N-terminus, the assembly domain (AD) mediates the oligomerization of the protein where 2 trimers form a hexameric structure. Between the EGF-like repeats and the carboxy terminal fibrinogen globe (FG) are Fibronectin type III repeats (FNIII). In human TNC, 9 of the total 17 FNIII repeats are alternatively spliced providing the possibility of multiple different TNC isoforms. (B) Several alternatively spliced FNIII repeats have been identified in cancer. FNIII domains A1 and C are expressed in lung cancer and A1 domain in renal cell carcinoma.39,40,52 Colorectal carcinoma (CRC) expresses domains A1, A2 and A4 which are specifically enriched in CRC when compared to total TNC expression.51 Head and neck cancer exhibits A1 and AD2 domains while melanoma expresses A1 and AD1.53–56 In urothelial carcinoma, domains A1, B, C and D are present and associate with invasive cancer.57,58 FNIII domain B is expressed in ovarian cancer and is enriched compared to the short TNC isoform (lacking all alternatively spliced FNIII domains).59 Breast cancer expresses B and D domains that are associated with invasive behavior and the AD1 domain.55,60 It is important to note that these lists are not exhaustive and only include the domains that have been positively linked to a particular cancer. Information of complete isoforms is generally lacking. However, while the knowledge of different TNC isoforms expressed in cancer is still rudimentary and incomplete, the appearance of different domains in cancers may indicate a requirement for distinct aspects of TNC functions.CC BY-NC · PubMed Central
Figure 2. TNC function in metastatic progression. At the primary tumor site, anti-adhesive TNC properties lead to alteration of intracellular pathways in cancer cells inducing the formation of actin-rich filopodia, favoring cell motility and invasive behavior. TNC is also associated with increased cancer cell proliferation and promotes angiogenesis within the tumor. At the secondary organ site, autocrine TNC supports cancer cell viability in a microenvironment that can exert a strong selective pressure. In breast cancer, TNC engages stem/progenitor signaling i.e. the Notch and Wnt pathways thereby promoting growth of micrometastasis. The development of macrometastasis is associated with reactive stroma which becomes a significant source of TNC protein.
Figure 2. TNC function in metastatic progression. At the primary tumor site, anti-adhesive TNC properties lead to alteration of intracellular pathways in cancer cells inducing the formation of actin-rich filopodia, favoring cell motility and invasive behavior. TNC is also associated with increased cancer cell proliferation and promotes angiogenesis within the tumor. At the secondary organ site, autocrine TNC supports cancer cell viability in a microenvironment that can exert a strong selective pressure. In breast cancer, TNC engages stem/progenitor signaling i.e. the Notch and Wnt pathways thereby promoting growth of micrometastasis. The development of macrometastasis is associated with reactive stroma which becomes a significant source of TNC protein.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 175 references

Research works printed but not linked: 16

  1. Bourdon MA, 1983, Cancer Res, 43, 2796
  2. 10.1002/1096-9896(2000)9999:9999%3c::AID-PATH752%3e3.0.CO;2-V · doi:10.1002/1096-9896(2000)9999:9999<::aid-path752>3.0.co;2-v
  3. Ishihara A, 1995, Clin Cancer Res, 1, 1035
  4. 10.1002/1097-0142(20010915)92:6%3c1419::AID-CNCR1465%3e3.0.CO;2-J · doi:10.1002/1097-0142(20010915)92:6<1419::aid-cncr1465>3.0.co;2-j
  5. 10.1002/(SICI)1097-0215(19970717)72:2%3c236::AID-IJC6%3e3.0.CO;2-S · doi:10.1002/(sici)1097-0215(19970717)72:2<236::aid-ijc6>3.0.co;2-s
  6. Adams M, 2002, Cancer Res, 62, 3289
  7. Zhao Y, 1995, Am J Physiol, 268, L173
  8. Cai M, 2002, Clin Cancer Res, 8, 1152
  9. 10.1002/(SICI)1097-0215(19961220)69:6%3c445::AID-IJC4%3e3.0.CO;2-4 · doi:10.1002/(sici)1097-0215(19961220)69:6<445::aid-ijc4>3.0.co;2-4
  10. Chiquet-Ehrismann R, 1989, Cancer Res, 49, 4322
  11. 10.1002/(SICI)1096-9896(199912)189:4%3c475::AID-PATH462%3e3.0.CO;2-V · doi:10.1002/(sici)1096-9896(199912)189:4<475::aid-path462>3.0.co;2-v
  12. Mori M, 1996, Anticancer Res, 16, 3075
  13. Herlyn M, 1991, Cancer Res, 51, 4853
  14. Takahashi Y, 2013, Anticancer Res, 33, 1927
  15. Huang W, 2001, Cancer Res, 61, 8586
  16. Tanaka S, 2010, Mol Vis, 16, 1194

Cited by

See all 178

Metadata

Authors
Lowy, C. M., & Oskarsson, T.
Affiliations
German Cancer Research Center (DE)
Venue
Cell Adhesion & Migration
Published
2015-01-02
Volume
9
Issue
1-2
Pages
112-124
ISSN
  • 1933-6918 (ISSN-L)
  • 1933-6926
OpenAlex
W1868626511
Cited by
178
References
166
Citations by year
2026: 8 · 2025: 9 · 2024: 10 · 2023: 16 · 2022: 25 · 2021: 26 · 2020: 27 · 2019: 21 · 2018: 14 · 2017: 13 · 2016: 7 · 2015: 2
FWCI
5.24
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Cell Adhesion & Migration (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords
tenascin-C, metastasis, extracellular matrix, tumor invasion, tumor cell migration, angiogenesis, metastatic niche, cancer stem cells, stem cell signaling, cancer cell fitness, poor prognosis
MeSH terms
Animals, Cell Adhesion, Cell Movement, Extracellular Matrix, Humans, Neoplasm Metastasis, Neoplasms, Tenascin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tenascin C in metastasis: A view from the invasive front. https://app.cochat.ai/papers/10.1080/19336918.2015.1008331
The paper
Lowy, C. M., & Oskarsson, T. (2015). Tenascin C in metastasis: A view from the invasive front. Cell Adhesion & Migration. https://doi.org/10.1080/19336918.2015.1008331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.